Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.

Salvador-Martín, Sara; Kaczmarczyk, Bartosz; Álvarez, Rebeca; Navas-López, Víctor Manuel; Gallego-Fernández, Carmen; Moreno-Álvarez, Ana; Solar-Boga, Alfonso; Sánchez, Cesar; Tolin, Mar; Velasco, Marta; Muñoz-Codoceo, Rosana; Rodriguez-Martinez, Alejandro; Vayo, Concepción A; Bossacoma, Ferrán; Pujol-Muncunill, Gemma; Fobelo, María J; Millán-Jiménez, Antonio; Magallares, Lorena; Martínez-Ojinaga, Eva; Loverdos, Inés; Eizaguirre, Francisco J; Blanca-García, José A; Clemente, Susana; García-Romero, Ruth; Merino-Bohórquez, Vicente; González de Caldas, Rafael; Vázquez, Enrique; Dopazo, Ana; Sanjurjo-Sáez, María; López-Fernández, Luis A

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/57179

Title:	Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
Authors:	Salvador-Martín, Sara Kaczmarczyk, Bartosz Álvarez, Rebeca Navas-López, Víctor Manuel Gallego-Fernández, Carmen Moreno-Álvarez, Ana Solar-Boga, Alfonso Sánchez, Cesar Tolin, Mar Velasco, Marta Muñoz-Codoceo, Rosana Rodriguez-Martinez, Alejandro Vayo, Concepción A Bossacoma, Ferrán Pujol-Muncunill, Gemma Fobelo, María J Millán-Jiménez, Antonio Magallares, Lorena Martínez-Ojinaga, Eva Loverdos, Inés Eizaguirre, Francisco J Blanca-García, José A Clemente, Susana García-Romero, Ruth Merino-Bohórquez, Vicente González de Caldas, Rafael Vázquez, Enrique Dopazo, Ana Sanjurjo-Sáez, María López-Fernández, Luis A View more
Keywords:	Crohn disease adalimumab biomarker gene expression inflammatory bowel disease infliximab ulcerative colitis View more
Issue Date:	8-Jan-2021
Citation:	Pharmaceutics.2021;(13)1:
Abstract:	Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in pediatric patients with IBD. An observational, longitudinal, prospective cohort study was conducted. The study population comprised 38 patients with IBD aged Genes were differentially expressed in non-responders and responders (32 before initiation of treatment and 44 after two weeks, Log2FC (Fold change) >0.6 or 0.6 or Expression of the FCGR1A, FCGR1B, and GBP1 genes is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD.
PMID:	33429950
URI:	https://hdl.handle.net/20.500.12530/57179
Rights:	openAccess
ISSN:	1999-4923
Appears in Collections:	Fundaciones e Institutos de Investigación > FIB H. Infantil U. Niño Jesús > Artículos

Files in This Item:

File	Size	Format
PMC7830359.pdf	4.86 MB	Adobe PDF	View/Open

Show full item record

This item is licensed under a Creative Commons License